Is There a Difference between Leads and Drugs? A Historical Perspective

Journal of Chemical Information and Computer Sciences

Volumn 41, Issue 3-6, 2001, Pages 1308-1315

  Oprea, Tudor I ^a   Davis, Andrew M ^b   Teague, Simon J ^b   Leeson, Paul D ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADSORPTION; DRUG THERAPY; HYDROGEN BONDS; HYDROPHOBICITY; METABOLISM; MOLECULAR WEIGHT;

HYDROGEN BOND DONORS (HDO);

MOLECULAR STRUCTURE;

LIGAND;

ARTICLE; COMBINATORIAL CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; DRUG SCREENING; FACTUAL DATABASE; HISTORY; STRUCTURE ACTIVITY RELATION;

COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HISTORY, 20TH CENTURY; LIGANDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035438391     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci010366a     Document Type: Article

References (30)

1. Chronicles of Drug Discovery; Bindra, J. S., Lednicer, D., Eds.; Wiley-Interscience: 1982; Vol. 1, ISBN 0-471-06516-1.
2. Chronicles of Drug Discovery; Bindra, J. S., Lednicer, D., Eds.; Wiley-Interscience: 1983; Vol. 2, ISBN 0-471-89135-5.
3. Chronicles of Drug Discovery; Lednicer, D., Ed.; ACS, Washington, 1993; Vol. 3, ISBN 0-8412-2733-0.
4. DeStevens, G. Serendipity and structured research in drug discovery. Prog. Drug. Res. 1986, 30, 189-203.
5. Scifinder 5.0, Copyright 1999; American Chemical Society: http:// www.acs.org.
6. Drews, J. Drug discovery: A historical perspective. Science 2000, 287, 1960-1964.
7. Furka, A. Combinatorial Chemistry. Chem. Intell. 1999, 5, 22-27.
8. Hirsch, P. F.; Anderson, J. J. B. Calcitonin. Calcium Phosphorus Health Dis. 1996, 197-206.
9. Ahn, S. H. What is medicinal chemistry. Hwahak Sekye 1994, 34, 109-111.
10. Ramsden, C. A. Medicinal chemistry: A multidisciplinary science. Sch. Sci. Rev. 1994, 75, 49-58.
11. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. I. The design of leadlike combinatorial libraries. Angew. Chem., Int. Ed. Engl. 1999, 38, 3743-3748; German version: Angew. Chem. 1999, 111, 3962- 3967.
12. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. I. The design of leadlike combinatorial libraries. Angew. Chem., Int. Ed. Engl. 1999, 38, 3743-3748; German version: Angew. Chem. 1999, 111, 3962-3967.
13. Hann, M. M.; Leach, A. R.; Harper, G. Molecular Complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
14. Sadowski, J.; Kubinyi, H. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 1998, 41, 3325-3329.
15. Ajay; Walters, W. P.; Murcko, M. A. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? J. Med. Chem. 1998, 41, 3314-3324.
16. Oprea, T. I. Property distribution of drug-related chemical databases. J. Comput-Aided Mol. Design 2000, 14, 251-264.
17. Oprea, T. I.; Gottfries, J.; Sherbuhin, V.; Svensson, P.; Kühler, T. C. Chemical information management in drug discovery: Optimizing the computational and combinatorial chemistry interfaces. J. Mol. Graphics Modelling 2000, 18, 512-524.
18. Olsson, T.; Sherbukhin, V. Synthesis and Structure Administration (SaSA); 1997-2001; AstraZeneca: http://www.astrazeneca.com.
19. The Daylight Toolkit and the physicochemical property calculations CMR and CLogP are available from Daylight Chemical Information Systems, Santa Fe, NM. http://www.daylight.com.
20. Downs, G. M. Ring Perception. In Encyclopedia of Computational Chemistry; von Ragué Schleyer, P., Ed.; Wiley: New York, 1998; Vol. 4, pp 2509-2515.
21. ACDLogP is available from ACD Labs, Toronto, Canada, http:// www.acdlabs.com/.
22. Several structures in Figures 2 and 3 were derived from the literature and are marked as such: For example, the compound marked JMC98_41_4556B in Figure 3 is from Aicher T. D., et al. J. Med. Chem. 1998, 41, 4556-4566; in another example, the compound marked BMCL96_6_1623A is from Ofner S., et al., Bioorg. Med. Chem. Lett. 1996, 6, 1623-1628; another example is MDDR_273694, which represents the identifier of that structure in the MDDR (MDL Drug Data Report) database, a collection of compounds patented for pharmaceutical use available from MDL (http://www.mdli.com).
23. Several structures in Figures 2 and 3 were derived from the literature and are marked as such: For example, the compound marked JMC98_41_4556B in Figure 3 is from Aicher T. D., et al. J. Med. Chem. 1998, 41, 4556-4566; in another example, the compound marked BMCL96_6_1623A is from Ofner S., et al., Bioorg. Med. Chem. Lett. 1996, 6, 1623-1628; another example is MDDR_273694, which represents the identifier of that structure in the MDDR (MDL Drug Data Report) database, a collection of compounds patented for pharmaceutical use available from MDL (http://www.mdli.com).
24. Several structures in Figures 2 and 3 were derived from the literature and are marked as such: For example, the compound marked JMC98_41_4556B in Figure 3 is from Aicher T. D., et al. J. Med. Chem. 1998, 41, 4556-4566; in another example, the compound marked BMCL96_6_1623A is from Ofner S., et al., Bioorg. Med. Chem. Lett. 1996, 6, 1623-1628; another example is MDDR_273694, which represents the identifier of that structure in the MDDR (MDL Drug Data Report) database, a collection of compounds patented for pharmaceutical use available from MDL (http://www.mdli.com).
25. Ganellin, C. R. Cimetidine. In Chronicles of Drug Discovery; Bindra, J. S., Lednicer, D., Eds.; Wiley-Interscience: 1982, Vol. 1, pp 1-38.
26. Bradshaw, J. Ranitidine. In Chronicles of Drug Discovery; Lednicer, D., Ed.; ACS: Washington DC, 1993; Vol. 3, pp 45-81.
27. Teutsch, G.; Deraedt, R.; Philibert, D. Mifepristone. In Chronicles of Drug Discovery; Lednicer, D., Ed.; ACS: Washington DC, 1993; Vol. 3, pp 1-43.
28. Inoue, H.; Nagao, T. Diltiazem. In Chronicles of Drug Discovery; Lednicer, D., Ed.: ACS: Washington DC, 1993; Vol. 3, pp 207-238.
29. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Reviews 1997, 23, 3-25.
30. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. 13th European QSAR Symposium, Düsseldorf, Germany, August 2000, poster.